Hanyu F, Nakamura M, Takasaki T, Kasai Y, Sato T, Sato H, Sakurai Y, Yamada A, Okawa T, Sakabe T
Dept. of Surgery, Institute of Gastroenterology, Tokyo Women's MedicalCollege.
Gan To Kagaku Ryoho. 1988 Nov;15(11):3087-93.
The composite substance of Mitomycin C (MMC) and polymer by low temperature radiating polymerization has a characteristic of slow release, the possibility of applying it to local chemotherapy was clinically studied. Buttom-formed preparation (MMC 20 mg) and needle-formed preparation (MMC 5 mg) were applied to the lesions, respectively, by sewing and piercing in 220 cancer patients with non resectable infiltrative lesions. The treatment had a pain-relieving effect in 70 out of 117 cases (60.0%) of painful cancer in the pancreas, biliary duct, liver, etc, and improved the symptoms of digestive organs in 31 out of 93 cases (33.3%). However, the tumor-reducing effect was recognized only in minute localized lesions of hepatic cancer, etc., and the survival period was not prolonged. The treatment caused no severe side effects. From the above results, the local chemotherapy with slow-releasing MMC preparation was concluded to be a useful means of palliative therapy in non-resectable, though its formulation may to be further improved.
丝裂霉素C（MMC）与聚合物通过低温辐射聚合形成的复合物具有缓释特性，对其应用于局部化疗的可能性进行了临床研究。分别采用缝入法和刺入法，将底部剂型制剂（MMC 20mg）和针状剂型制剂（MMC 5mg）应用于220例具有不可切除浸润性病变的癌症患者的病灶。该治疗对117例胰腺、胆管、肝脏等疼痛性癌症中的70例（60.0%）有止痛效果，对93例中的31例（33.3%）改善了消化器官症状。然而，仅在肝癌等微小局限性病变中观察到肿瘤缩小效果，且生存期未延长。该治疗未引起严重副作用。从上述结果得出，缓释MMC制剂的局部化疗是不可切除性癌症姑息治疗的一种有用方法，尽管其剂型可能有待进一步改进。
